Molecular profiling of drug resistant triple negative breast cancer

Principal Investigator: Mark Basik
Theme : Health
Competition : Genomics research in human health - general stream
Status : Completed
Start : Oct. 1, 2010
End: Mar. 31, 2015
Budget : $2,168,293.00

Although we understand the differences between tumour cells and normal cells, so much so that we can target these differences, metastatic tumours, including those resistant to therapy, are less known because it is much harder to obtain samples from those sites (liver, lung, skin).

This project will directly address this problem. Patients treated for the most aggressive type of breast cancer (triple negative) will be recruited in four Québec hospitals. Biopsies will then be obtained before treatment with the most powerful drugs in breast cancer, and after the treatment. These two samples will then be analyzed to identify the molecular factors of resistance to treatment.

These factors of resistance can help oncologists in two ways: first, by using these factors of resistance, it will be possible to better adapt the treatment to each patient; and second, it will be possible to target the identified factors to develop new treatments to overcome the resistance in advanced tumours.



Gerald Batist Lady Davis Institute for Medical Research
Alberto Cambrosio McGill University
Peter Keating Université du Québec à Montréal
Jonathan Kimmelman McGill University
Jacek Majewski McGill University